Valneva SE: Difference between revisions

Latest revision as of 03:46, 13 February 2025

Valneva SE logo

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is headquartered in Saint-Herblain, France, and operates globally.

History[edit]

Valneva SE was formed in 2013 through the merger of Vivalis SA and Intercell AG. The merger combined Vivalis's expertise in vaccine development and Intercell's innovative vaccine technologies. Since its inception, Valneva has focused on developing vaccines for infectious diseases, leveraging its proprietary technology platforms.

Technology Platforms[edit]

Valneva utilizes several proprietary technology platforms in its vaccine development efforts:

Vero-cell platform: This platform is used for the production of inactivated whole virus vaccines. It is a well-established technology that Valneva employs for its Japanese encephalitis and COVID-19 vaccine candidates.

EB66® cell line: Originally developed by Vivalis, this cell line is used for the production of vaccines and therapeutic proteins. It is derived from duck embryonic stem cells and is known for its high yield and scalability.

IC31® adjuvant: This adjuvant technology enhances the immune response to vaccines. It is used in several of Valneva's vaccine candidates to improve their efficacy.

Vaccine Portfolio[edit]

Valneva's vaccine portfolio includes both marketed products and candidates in various stages of development:

IXIARO®: A vaccine for the prevention of Japanese encephalitis, a mosquito-borne viral infection. It is approved in several countries and is primarily used by travelers and military personnel.

VLA2001: A COVID-19 vaccine candidate based on the inactivated whole virus approach. It is designed to provide broad protection against the SARS-CoV-2 virus.

VLA1553: A single-shot vaccine candidate for Chikungunya, a mosquito-borne viral disease. It is currently in clinical trials.

Research and Development[edit]

Valneva invests significantly in research and development to expand its vaccine portfolio. The company collaborates with various organizations, including government agencies and pharmaceutical companies, to advance its vaccine candidates.

Global Operations[edit]

Valneva operates manufacturing sites in Scotland and Sweden, and has offices in several countries, including the United States, Austria, and United Kingdom. The company markets its products globally and continues to expand its international presence.

Related pages[edit]

@@ Line 1: / Line 1: @@
-'''Valneva SE''' is a [[biotechnology]] and [[pharmaceutical company]] that specializes in the development, manufacturing, and commercialization of [[vaccines]] for infectious diseases with major public health implications. The company, headquartered in [[Saint-Herblain]], [[France]], has a significant presence in the global vaccine market, focusing on travel and endemic vaccines.
+{{DISPLAYTITLE:Valneva SE}}
+[[File:Valneva logo.svg|thumb|right|Valneva SE logo]]
+'''Valneva SE''' is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is headquartered in [[Saint-Herblain]], [[France]], and operates globally.
 ==History==
-Valneva SE was formed through the merger of [[Intercell AG]], an Austrian biotech company, and [[Vivalis SA]], a French biopharmaceutical company, in 2013. This strategic merger combined Intercell's expertise in vaccine development with Vivalis's innovative cell line manufacturing technologies, positioning Valneva as a leader in the vaccine industry.
+Valneva SE was formed in 2013 through the merger of [[Vivalis SA]] and [[Intercell AG]]. The merger combined Vivalis's expertise in vaccine development and Intercell's innovative vaccine technologies. Since its inception, Valneva has focused on developing vaccines for infectious diseases, leveraging its proprietary technology platforms.
+==Technology Platforms==
+Valneva utilizes several proprietary technology platforms in its vaccine development efforts:
+* '''Vero-cell platform''': This platform is used for the production of inactivated whole virus vaccines. It is a well-established technology that Valneva employs for its [[Japanese encephalitis]] and [[COVID-19]] vaccine candidates.
+* '''EB66® cell line''': Originally developed by Vivalis, this cell line is used for the production of vaccines and therapeutic proteins. It is derived from duck embryonic stem cells and is known for its high yield and scalability.
+* '''IC31® adjuvant''': This adjuvant technology enhances the immune response to vaccines. It is used in several of Valneva's vaccine candidates to improve their efficacy.
+==Vaccine Portfolio==
+Valneva's vaccine portfolio includes both marketed products and candidates in various stages of development:
-==Products and Research==
+* '''IXIARO®''': A vaccine for the prevention of Japanese encephalitis, a mosquito-borne viral infection. It is approved in several countries and is primarily used by travelers and military personnel.
-Valneva's product portfolio includes vaccines for [[Japanese encephalitis]] (IXIARO®/JESPECT®), [[Cholera]] (DUKORAL®), and [[Lyme disease]], among others. The company is also known for its development of a single-shot [[chikungunya]] virus vaccine, which has reached Phase 3 clinical trials, showcasing Valneva's commitment to addressing global health challenges.
-One of Valneva's most notable achievements is its development of a candidate vaccine for [[COVID-19]], leveraging its established platform and expertise in vaccine research and development. This effort highlights the company's agility in responding to emergent global health crises.
+* '''VLA2001''': A COVID-19 vaccine candidate based on the inactivated whole virus approach. It is designed to provide broad protection against the SARS-CoV-2 virus.
-==Operations==
+* '''VLA1553''': A single-shot vaccine candidate for [[Chikungunya]], a mosquito-borne viral disease. It is currently in clinical trials.
-Valneva operates several state-of-the-art manufacturing facilities across Europe, including in [[Scotland]], [[Sweden]], and [[Austria]], which are pivotal in the production of its vaccines. These facilities adhere to the highest standards of quality and safety, ensuring the global distribution of vaccines to combat infectious diseases.
-==Collaborations and Partnerships==
+==Research and Development==
-Valneva has established numerous partnerships with governments, global health organizations, and other pharmaceutical companies to expand its vaccine distribution and development capabilities. These collaborations are crucial for advancing vaccine research and making vaccines more accessible worldwide.
+Valneva invests significantly in research and development to expand its vaccine portfolio. The company collaborates with various organizations, including government agencies and pharmaceutical companies, to advance its vaccine candidates.
-==Financial Performance==
+==Global Operations==
-As a publicly traded company on the Euronext Paris and the Nasdaq Stock Market, Valneva has demonstrated strong financial performance, with steady revenue growth driven by vaccine sales and development contracts. The company's financial health is critical for sustaining its research and development efforts and expanding its vaccine portfolio.
+Valneva operates manufacturing sites in [[Scotland]] and [[Sweden]], and has offices in several countries, including the [[United States]], [[Austria]], and [[United Kingdom]]. The company markets its products globally and continues to expand its international presence.
-==Challenges and Future Directions==
+==Related pages==
-Valneva faces challenges common to the pharmaceutical industry, including regulatory hurdles, competition, and the complexities of vaccine development. However, the company's focus on niche markets, such as travel vaccines and diseases with unmet medical needs, positions it well for future growth. Valneva continues to invest in research and development to expand its vaccine portfolio, with a strong pipeline of vaccine candidates addressing various infectious diseases.
+* [[Vaccine]]
+* [[Infectious disease]]
+* [[Biotechnology]]
 [[Category:Pharmaceutical companies of France]]
-[[Category:Biotechnology companies]]
 [[Category:Vaccine producers]]
+[[Category:Companies established in 2013]]
-{{pharma-stub}}